


## AMENDMENTS TO THE CLAIMS

This listing replaces all prior versions and listings of claims in the application.

### Listing of Claims

1 - 63. (Cancelled).

64. (Currently Amended) A composition comprising a combination of  
i) a fatty acid mono-ester or di-ester of formula I or an isomer thereof,



**I**

wherein:

n is 3;

each of  $R^1$  and  $R^2$  is independently selected from the group consisting of H, OH, OM, OR', O-CO-R', straight-chain or branched  $C_1$ - $C_6$  alkyl and straight-chain or branched  $C_2$ - $C_6$  alkenyl, provided that one or two of  $R^1$  and  $R^2$  is -O-CO-R' and at least one of  $R^1$  and  $R^2$  is OH; and

$R'$  is  $C_6$ - $C_{14}$   $C_6$ - $C_{10}$  alkyl and M is an alkali metal,

and

ii) niacinamide, a salt or a derivative thereof, wherein the derivative is selected from the group consisting of (a) niacinamide derivatives with one substitution of the ring, with substituents selected from halogen,  $NH_2$ , methyl, OR and SH and (b) niacinamide derivatives wherein the amide group is in the form of its secondary amide or its tertiary amide.

65. (Cancelled).

66. (Previously Presented) The composition according to claim 64, wherein R' is selected from unsubstituted straight-chain or branched C<sub>6</sub>-C<sub>12</sub> alkyl.

67. (Previously Presented) The composition according to claim 64, wherein O-CO-R' is an acyloxy moiety derived from an acid, HO-CO-R', selected from the group consisting of caproic acid, caprylic acid, capric acid, lauric acid and myristic acid.

68. (Cancelled)

69. (Previously Presented) The composition according to claim 64, wherein the niacinamide, salt and a derivative thereof is selected from the group consisting of niacinamide, thioniacinamide, 6-amino-niacinamide, N<sup>2</sup>-methylniacinamide, N<sup>2</sup>-ethylniacinamide, 6-methoxy-niacinamide and salts thereof.

70. (Previously Presented) The composition according to claim 64, wherein the pyridine derivative is niacinamide or a salt thereof.

71. (Currently Amended) The composition according to claim 64, wherein the fatty acid ester and the niacinamide, a salt or a derivative thereof are present in a molar ratio of between about 1:10000 to 10000:1, ~~preferably about 1:1000 to 1000:1, more preferably of about 1:100 to 100:1, even more preferably of about 1:10 to 10:1, most preferably of about 1:5 to 5:1 or about 1:2 to 2:1.~~

72. (Previously Presented) The composition according to claim 64, wherein the fatty acid ester is racemic, enantiomerically enriched or enantiomerically pure 1-glyceryl-monocaprylate and wherein the niacinamide, salt or a derivative thereof is niacinamide.

73. (Previously Presented) The composition according to claim 64, further comprising one or more excipient(s) or carrier(s) for the formulation of a pharmaceutical, a dietary supplement or a cosmetic.

74. (Previously Presented) The composition according to claim 73, further comprising one or more therapeutically active agents.

75. (Previously Presented) The composition according to claim 73, formulated for oral, topical, transdermal, or parenteral administration.

76. (Previously Presented) The composition according to claim 75, formulated for topical administration.

77. (Cancelled)

78. (Cancelled)

79. (Withdrawn Currently Amended) A method for treating conditions selected from the group consisting of acne, acne prone skin, irritated skin, dry skin, skin redness, scaly or flaking skin, and sunburn, comprising administering a composition as defined in claim 64.

80. (Cancelled)

81. (Withdrawn) A method for the treatment of infections or diseases associated with infections selected from the group consisting of microbial infections, viral infections, infections caused by parasites, infections caused by fungi in a mammal, including a human, comprising the administration to said mammal an effective amount of a combination of a fatty acid mono-ester or di-ester of formula I and niacinamide, a salt or a derivative thereof, wherein formula I, n, R<sup>1</sup>, R<sup>2</sup>, R', M and the niacinamide derivative are as defined in claim 64.

82. (Withdrawn) A method for the treatment of viral infections or diseases associated with viral infections in a mammal, including a human, comprising the administration to said mammal an effective amount of a combination of a fatty acid mono-ester or di-ester of

formula and niacinamide, a salt or a derivative thereof, wherein formula I, n, R<sup>1</sup>, R<sup>2</sup>, R', M and the niacinamide derivative are as defined in claim 64.

83. (Withdrawn) The method according to claim 82, for the treatment, alleviation or prevention of infection with virus or a disease associated with infection with virus selected from the group consisting of herpesviruses, adenoviruses, papovaviruses, parvoviruses, picornaviruses, reoviruses, togaviruses, bunyaviruses, orthomyxoviruses, paramyxoviruses, rhabdoviruses, retroviruses, arenaviruses, poxviruses, hepadnaviruses, caliciviruses, flaviviruses, coronaviruses, filoviruses and orthomyxoviruses.

84. (Withdrawn) The method according to claim 82, for the treatment, alleviation or prevention of infection with virus or a disease associated with infection with virus selected from the group consisting of rhinovirus, influenzavirus, hepatitisvirus, herpesvirus and cytomegalovirus.

85. (Withdrawn) The method according to claim 82, for the treatment, alleviation or prevention of a disease associated with infection with virus selected from the group consisting of common cold, influenza viral pharyngitis, viral pneumonia and viral hepatitis in an individual.


86. (Withdrawn) A method for the treatment of a disease and disorder associated with hypersensitivity and/or inflammatory reactions, including a human, comprising the administration to said mammal an effective amount of a combination of a fatty acid mono-ester or di-ester of formula I and niacinamide, a salt or a derivative thereof, wherein formula I, n, R<sup>1</sup>, R<sup>2</sup>, R', M and the niacinamide derivative are as defined in claim 64.

87. (Withdrawn) The method according to claim 86, wherein said disease and disorder is selected from the group consisting of hypersensitivity skin disease, pruritus, urticaria, atopic eczema, contact dermatitis, seborrhoeic dermatitis, acne, rosacea, alopecia, vitiligo, psoriasis IgE mediated allergic reactions, asthma, allergic rhinitis, anaphylaxis, autoimmune disease, chronic inflammatory disease, Crohn's disease, ulcerative colitis,

rheumatoid arthritis, gout, osteoarthritis, inflammation associated with pain and inflammation associated with cancer.

88. (Withdrawn) The method according to claim 81, comprising administering a composition comprising a combination of:

i) a fatty acid ester in the form of a mono-ester or in the form of a di-ester of formula I or isomers thereof,



wherein:

n is 3;

each  $R^1$  and  $R^2$  is independently selected from the group consisting of H, OH, OM, OR', O-CO-R', straight-chain or branched  $C_1$ - $C_6$  alkyl and straight-chain or branched  $C_2$ - $C_6$  alkenyl, provided that one or two of  $R^1$  and  $R^2$  is -O-CO-R' and at least one of  $R_1$  and  $R_2$  is OH; and

$R'$  is selected from the group consisting of  $C_6$ - $C_{14}$  alkyl, and M is an alkali metal[[;]], and

ii) niacinamide, a salt or a derivative thereof, wherein the derivative is selected from the group consisting of niacinamide derivatives with one substitution of the ring with substituents selected from halogen,  $NH_2$ , methyl, OR and SH and from niacinamide derivatives wherein the amide group is in the form of its secondary amide or its tertiary amide.

89. (Withdrawn) The method according to claim 81, wherein the fatty acid mono-ester or di-ester of formula I and niacinamide, a salt or a derivative thereof are together comprised in a single formulation or are each individually comprised in separate formulations.

90. (Withdrawn) The method according to claim 81, wherein fatty acid mono-ester or di-ester of formula I and niacinamide, a salt or a derivative thereof is administered by means of oral, topical, transdermal, or parenteral administration, or combinations thereof.

91. (Withdrawn) The method according to claim 81, wherein the medicament further comprises one or more therapeutically active agents.

92. (Withdrawn) The method according to claim 91, wherein the separate formulations are administered in a simultaneous or non-simultaneous manner.

93. (New) The composition according to claim 71, wherein the fatty acid ester and the niacinamide, a salt or a derivative thereof are present in a molar ratio of between about 1:1000 to 1000:1.

94. (New) The composition according to claim 93, wherein the fatty acid ester and the niacinamide, a salt or a derivative thereof are present in a molar ratio of between about 1:100 to 100:1.

95. (New) The composition according to claim 94, wherein the fatty acid ester and the niacinamide, a salt or a derivative thereof are present in a molar ratio of between about 1:10 to 10:1.

96. (New) The composition according to claim 95, wherein the fatty acid ester and the niacinamide, a salt or a derivative thereof are present in a molar ratio of between about 1:5 to 5:1 or about 1:2 to 2:1.